Tara I-O 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   2 Trials   38 News 
  • ||||||||||  p53MVA - Tara I / O
    Enrollment change, Trial completion date, Combination therapy:  Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) -  Mar 21, 2023   
    P1,  N=11, Active, not recruiting, 
    Detection of markers of terminally differentiated T cells before treatment may identify patients unlikely to respond to p53MVA/pembrolizumab. N=19 --> 11 | Trial completion date: Dec 2022 --> Dec 2023
  • ||||||||||  shIDO-ST - Tara I / O, epacadostat (INCB024360) / Incyte
    Journal, PD(L)-1 Biomarker, IO biomarker:  Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. (Pubmed Central) -  May 11, 2021   
    Although increased tumor expression of IDO is associated with resistance to antibody therapy against programed cell death-1 (anti-PD1), co-administration of anti-PD1 with shIDO-ST did not provide additional tumor growth control in either model of colorectal cancer. Altogether, we demonstrate that treatment with shIDO-ST markedly delays tumor growth in two immunocompetent colorectal mouse models and this appears to be a superior therapeutic strategy compared to epacadostat or blocking anti-PD1 antibody therapy in colon cancer.
  • ||||||||||  p53MVA - Tara I / O
    Trial completion date, Combination therapy:  Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) -  Mar 10, 2021   
    P1,  N=19, Active, not recruiting, 
    Altogether, we demonstrate that treatment with shIDO-ST markedly delays tumor growth in two immunocompetent colorectal mouse models and this appears to be a superior therapeutic strategy compared to epacadostat or blocking anti-PD1 antibody therapy in colon cancer. Trial completion date: Feb 2020 --> Dec 2021
  • ||||||||||  shIDO-ST - Tara I / O
    Clinical, Journal, Checkpoint inhibition, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. (Pubmed Central) -  Dec 21, 2020   
    These results suggest that the success of ICB therapy may be more accurately predicted by taking into account multiple factors such as potential for antigen presentation and immune subset repertoire in addition to markers already being considered. Alternatively, combination treatment with agents such as shIDO-ST could be used to create a more conducive tumor microenvironment for improving responses to ICB.
  • ||||||||||  p53MVA - Tara I / O
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) -  Feb 23, 2020   
    P2,  N=28, Recruiting, 
    Alternatively, combination treatment with agents such as shIDO-ST could be used to create a more conducive tumor microenvironment for improving responses to ICB. Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), p53MVA - Tara I / O
    Clinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. (Pubmed Central) -  May 22, 2019   
    Therefore, if responses to p53MVA could be enhanced with alternative agents, superior clinical responses may be achievable. We have shown that the combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies.
  • ||||||||||  p53MVA - Tara I / O
    Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker:  Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) -  Apr 30, 2019   
    P1,  N=19, Active, not recruiting, 
    We have shown that the combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies. Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Feb 2020
  • ||||||||||  p53MVA - Tara I / O
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) -  Apr 30, 2018   
    P1,  N=12, Completed, 
    Trial completion date: Apr 2018 --> Feb 2019 | Trial primary completion date: Apr 2018 --> Feb 2019 Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Apr 2018 | Trial primary completion date: Aug 2018 --> Apr 2018
  • ||||||||||  p53MVA - Tara I / O
    Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker:  Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) -  Nov 14, 2015   
    P1,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Nov 2015 | Trial primary completion date: May 2017 --> Nov 2016
  • ||||||||||  p53MVA - Tara I / O
    Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker:  Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) -  Nov 8, 2015   
    P1,  N=12, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Nov 2015 | Trial primary completion date: May 2017 --> Nov 2016 Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Oct 2016 --> May 2017